Vaccination Against COVID-19 in Chronic Kidney Disease

NCT ID: NCT04743947

Last Updated: 2022-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-21

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multi-center, observational study that will enroll patients receiving dialysis (hemodialysis or peritoneal dialysis) or patients with kidney transplantation who will be vaccinated against COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients on dialysis and kidney transplant patients infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) have an increased risk to develop a more severe course of disease or die from COVID-19 (coronavirus disease 2019). SARS-CoV-2 vaccination can increase protection against COVID-19. Kidney transplant patients and patients requiring dialysis suffer from an acquired immune deficiency. Due to the dysfunctional immune response, the general vaccine response in dialysis patients and kidney transplant patients is in many cases insufficient.

Until now, the vaccination response in dialysis patients and kidney-transplanted patients is unpredictable. Verification of vaccine response can provide important information on how to treat and protect these patients from a COVID-19. Therefore, there is a medical need to monitor vaccine protection after SARS-CoV-2 vaccination in clinical practice. In this observational study, data of the SARS-CoV-2 vaccination response collected in clinical routine will be analyzed from these patients. Based on this observational study, the investigators aim to get first evidence whether and to what extent vaccination against COVID-19 causes a vaccine response in immunocompromised patients with kidney disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease Stage 5 on Dialysis Chronic Kidney Disease Stage 5 With Transplant Vaccine Response Impaired

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with kidney failure receiving dialysis

Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in dialysis patients (hemodialysis or peritoneal dialysis).

No intervention; observational study

Intervention Type OTHER

no intervention

Kidney transplant patients

Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in kidney transplant patients.

No intervention; observational study

Intervention Type OTHER

no intervention

age-matched controls in non-dialysis, non-kidney transplant patients

Historical cohort of aged matched non-dialysis and non-kidney transplanted patients who received a SARS-CoV-2 vaccination.

No intervention; observational study

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention; observational study

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* receiving dialysis (hemodialysis or peritoneal dialysis)
* capable of giving consent
* age 18 or older

Exclusion Criteria

\- non-capable of giving consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heinrich-Heine University, Duesseldorf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

PD Dr. med. Johannes Stegbauer

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MVZ DaVita Rhein-Ruhr

Düsseldorf, , Germany

Site Status RECRUITING

KfH Kuratorium für Dialyse und Nierentransplantation e.V.

Düsseldorf, , Germany

Site Status RECRUITING

University Hospital Düsseldorf, Heinrich Heine University

Düsseldorf, , Germany

Site Status RECRUITING

Nephrocare Mettmann

Mettmann, , Germany

Site Status RECRUITING

Hospital Solingen

Solingen, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Johannes Stegbauer, MD

Role: CONTACT

+492118117502

Claudia Schmidt, PhD

Role: CONTACT

+492118108074

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gerd Hetzel, Prof. MD

Role: primary

0211 16797-30

Lars Christian Rump, Prof. MD

Role: primary

0211 876696-0

Johannes Stegbauer, MD

Role: primary

+492118117502

Michael Koch, Prof. MD

Role: primary

02051 4197-0

Michael Schmitz, MD

Role: primary

0212-547-2418

References

Explore related publications, articles, or registry entries linked to this study.

Kolb T, Fischer S, Muller L, Lubke N, Hillebrandt J, Andree M, Schmitz M, Schmidt C, Kucukkoylu S, Koster L, Kittel M, Weiland L, Dreyling KW, Hetzel G, Adams O, Schaal H, Ivens K, Rump LC, Timm J, Stegbauer J. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients. Kidney360. 2021 Jul 13;2(9):1491-1498. doi: 10.34067/KID.0003512021. eCollection 2021 Sep 30.

Reference Type DERIVED
PMID: 35373105 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-1237

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Donor Simvastatin Treatment in Organ Transplantation
NCT01160978 COMPLETED PHASE2/PHASE3
HCV + to HCV - Kidney Transplant
NCT04320290 WITHDRAWN PHASE4